MHC Multimer Proficiency Panel Report 2020
MHC Multimer Proficiency Panel Report 2019
MHC Multimer Proficiency Panel Report 2018
MHC Multimer Proficiency Panel Report 2017
Originally developed at the initiative of CIC (the US Cancer Immuno-therapy Consortium of the CRI) and CIMT (the European Association for Cancer Immunotherapy), Immudex offers Proficiency Testing as a non-profit service to help researchers and clinicians worldwide evaluate and benchmark their immune monitoring performance with MHC Multimers.
Using laboratory-specific protocols, antibodies, and flow cytometry, participants determine the number of antigen-specific T cells in provided PBMC samples using MHC multimers and receive a report comparing the results from all participating laboratories.
PBMC samples: identical for all participants*
If requested, MHC Dextramer® reagents free of charge (only pay shipping fees)
Total number of CD8+ T cells in samples
Number of MHC multimer+ CD8+ T cells in samples
Percent of total CD8+ T cells that are MHC multimer+
In the MHC Multimer Proficiency Panel 2021, all laboratories received identical PBMC samples for identification of antigen-specific T-cells using MHC multimers, and results were collated to assess the relative accuracy of results across the different laboratories. 13 out of 19 participants (68,4%) had a relative accuracy between 0.66 – 1.5 and were considered to be in “the average range” (dark blue columns).
Learn more in the MHC Multimer Proficiency Panel Report 2021
*Immudex conducts quality control of the PBMC samples before these are shipped to participants.
|Academia and Non-profit Organizations||To be determined|
|Industry companies and CROs||To be determined|
Registration for the MHC Multimer Proficiency Testing Service 2023 opens in Spring 2023. Contact us at email@example.com if you’d like to be informed when registration opens.